(Q30658857)

26 June 2017

PCV for oligodendroglial tumors: in search of prognostic factors for response and survival (English)

1 reference

26 June 2017

1 reference

4

Cairncross JG

1 reference

26 June 2017

Fortin D

1

1 reference

26 June 2017

Macdonald DR

series ordinal

2

1 reference

26 June 2017

Stitt L

series ordinal

3

1 reference

26 June 2017

1 August 2001

1 reference

Canadian Journal of Neurological Sciences

26 June 2017

1 reference

26 June 2017

28

1 reference

26 June 2017

3

1 reference

26 June 2017

215-223

1 reference

Prognostic relevance of DNA flow cytometry in oligodendroglioma

26 June 2017

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Histopathology, classification, and grading of gliomas

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Oligodendroglioma: the Rotterdam-Dijkzigt experience.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Salvage chemotherapy for oligodendroglioma.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Grading of oligodendrogliomas.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Oligodendroglioma: incidence and biological behavior in a defined population

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Grading of astrocytomas. A simple and reproducible method.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Is necrosis helpful in the grading of gliomas? Editorial opinion

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Mixed oligoastrocytomas: a survival and prognostic factor analysis.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Pre-radiation chemotherapy for malignant glioma in adults

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Cerebral oligodendroglioma: prognostic factors and life history.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Prognostic significance of flow cytometry deoxyribonucleic acid analysis of human oligodendrogliomas.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

The treatment of anaplastic oligodendrogliomas and mixed gliomas.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Low-grade oligodendroglioma responds to chemotherapy.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

High-dose thiotepa with autologous bone marrow rescue in recurrent malignant oligodendroglioma: a case report.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Clinicopathologic correlations in the oligodendroglioma.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Management of oligodendrogliomas.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Oligoastrocytomas: a clinicopathological study of 52 cases.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Proliferation of gemistocytic cells and glial fibrillary acidic protein (GFAP)-positive oligodendroglial cells in gliomas: a MIB-1/GFAP double labeling study.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

The role of postoperative irradiation in the treatment of oligodendroglioma.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Supratentorial gliomas: a comparative study by grade and histologic type.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Oligodendroglioma. A comparison of two grading systems

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Oligodendrogliomas: the Mayo Clinic experience

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

The prognostic significance of Ki-67 labeling indices for oligodendrogliomas.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

Successful chemotherapy for recurrent malignant oligodendroglioma.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100001359

7 January 2021

10.1017/S0317167100001359

Identifiers

DOI

0 references

1 reference